MD Total Wellness
MD Total Wellness is an in-person Brea practice with named clinicians and continuing appointments. Its peptide menu also advertises investigational compounds, including retatrutide, making regulatory status and evidence essential questions.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
The local clinical relationship is clearly described, but it does not resolve concerns about every advertised compound. Discuss approved options and independent evidence, and do not treat a research-peptide label or a clinician’s supervision as proof of an authorized medicine.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
MD Total Wellness provides weight, hormone and peptide care from a Brea, California office. The service is different from a nationwide questionnaire-only platform: initial peptide visits must be in person, with later follow-up potentially by telehealth. Treatment selection should begin with the actual diagnosis and available established options.
What MD Total Wellness prescribes, by goal
Weight
- SemaglutideFDA-approved
Listed by the seller; no price we hold.
- TirzepatideFDA-approved
Listed by the seller; no price we hold.
Semaglutide and tirzepatide are named in the weight-care program, which also advertises retatrutide. FDA states that retatrutide is not an approved-drug component and cannot be used in compounding under federal law. Its presence should not be interpreted as an approved treatment option.
Sexual health
- PT-141 (bremelanotide)FDA-approved
Listed by the seller; no price we hold.
Longevity
- NAD+Compounding conditions apply
- Injection (compounded)Price not published
The menu names NAD+, sermorelin, tesamorelin and other compounds. Confirm the actual preparation, authorization, monitoring and evidence; broad anti-aging language does not establish a meaningful benefit.
Recovery
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
The recovery menu includes BPC-157, TB-500 and combination protocols. Claims about faster tissue healing require human clinical evidence for the actual product and indication, not just a proposed biological mechanism.
Sleep
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
Sleep and cognitive claims are attached to several experimental peptide listings. A clinic menu does not establish that those products have been shown safe and effective for the advertised goal.
Who prescribes
A licensed clinician
The practice names individual clinicians: David Oliak, MD, Allison Mollet, PA-C, and Lindsay Riding, PA-C. Its own biographies describe their professional backgrounds. Verify the current license and who will manage your specific care rather than interpreting a clinic-wide physician-led description as a guarantee that every encounter is with a physician.
The program describes a consultation before any prescription. GLP-1 care includes monthly clinical check-ins, nutrition guidance and body-composition tracking. The peptide service requires an initial visit in Brea and permits later in-person or telehealth follow-up. Ask who handles side effects between appointments, when reassessment is required and what records are shared with your regular clinician.
Are labs required?
Required for some protocols; price unconfirmed
The service explicitly requires initial testing and a comprehensive evaluation for growth-hormone-stimulating peptides such as sermorelin and tesamorelin. Other named protocols have a separate consultation pathway. Ask for the treatment-specific panel, interpretation, repeat interval and complete testing charge; a general evaluation benefit is not a universal allowance.
Ready to start with MD Total Wellness?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
The clinic makes strong claims for recovery, cognition and longevity across compounds with very different evidence and regulatory status. Its weight page lists retatrutide as a research peptide beside conventional GLP-1 programs. FDA’s current guidance says retatrutide cannot be compounded under federal law. That general FDA position is distinct from a provider-specific enforcement finding; no matching direct letter was identified in the limited brand and clinician index screen. A compound’s participation in research is not approval for routine patient use. Request evidence relevant to the actual preparation, condition and proposed monitoring before considering any experimental protocol.
Other products and treatment claims
- Tesamorelin
- Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.
- Ipamorelin
- "Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.
- CJC-1295
- On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it.
- BPC-157
- On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- TB-500
- On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- KPV
- On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- MOTS-c
- On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- Epitalon
- On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
- Semax
- On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- Selank
- On no FDA compounding list. Selank appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- DSIP
- On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
- Retatrutide
- FDA states that retatrutide and cagrilintide "cannot be used in compounding under federal law", and that they "are not components of FDA-approved drugs and have not been found safe and effective for any condition". It is named on no 503A or 503B list.
How it bills
The GLP-1 page describes regular monthly semaglutide and tirzepatide program prices after lower starting-dose months. Those program amounts do not establish the precise dispensed form. Other peptides have a separate consultation and evaluation pathway; the menu is not a complete medication quote. The service offers California fulfillment and office pickup. Confirm the pharmacy, written prescription, appointment charges and cancellation terms. A starting consultation should not be assumed to commit you to every optional diagnostic or adjunct treatment.
For and against
- For: Treating clinicians named
- For: Initial in-person relationship and continuing appointments
- For: Specific monitoring requirements acknowledged
- Against: Investigational retatrutide actively advertised
- Against: Broad experimental-peptide efficacy claims
- Against: Medication forms, pharmacy and complete protocol costs need confirmation
The evidence behind what it sells
- Semaglutide Side Effects: What the Wegovy Trials and Label Recorded
- Bremelanotide Side Effects: Nausea, Blood Pressure and Skin Darkening
- NAD Side Effects: What Injection, IV and Oral Precursor Studies Reported
- Sermorelin Side Effects: What the Trials and FDA Record Report
- Tirzepatide Side Effects: What the Zepbound Label and Trials Recorded
- Bremelanotide (PT-141): The FDA Approval and What the Trials Showed
Right for
A California patient seeking an in-person clinical discussion who will critically assess the actual treatment and approved alternatives.
Look elsewhere if
Someone interpreting a physician-owned practice or research label as evidence that every offered compound is approved or suitable.
Other sellers for weight
AM Rx
Also prescribes Semaglutide, Tirzepatide.
Surfbound Health
Also prescribes Semaglutide, Tirzepatide.
Hims
Also prescribes Semaglutide, Tirzepatide.
MD Total Wellness
Frequently asked questions
- Is the first peptide visit entirely online?
- The peptide service requires the initial visit in Brea. Later follow-up can be in person or by telehealth.
- Does the clinic name its clinicians?
- Yes. The public team includes David Oliak, Allison Mollet and Lindsay Riding; confirm who will manage your prescription.
- Does research peptide mean approved treatment?
- No. FDA specifically says retatrutide cannot be used in compounding under federal law.
Sources
- Current local practice and services
- Named treating team and in-person model
- GLP-1 package, regular rates and retatrutide offer
- Peptide consultation, monitoring and California fulfillment
- Specific named peptide menu and claims
- FDA restrictions and concerns about unapproved GLP-1 drugs
See what MD Total Wellness prescribes today
MD Total Wellness sets its own prices, plans and the states it serves. Check them before you start.